Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Eit Pharma Inc. is currently managing 1 pending office action in the Biotechnology & Pharmaceuticals technology area. The busiest examiner for the company is JOSEPH, JANET, who has 1 pending action. The prosecution activity is concentrated in 1 distinct examiner and 1 distinct art unit. This means the 1 pending office action represents the total current workload for the company at the USPTO.
For the practitioner, the focus on a single examiner in the Biotechnology & Pharmaceuticals area suggests that the outcome of the 1 pending action will depend entirely on that individual's review. The concentration in 1 distinct art unit implies that the claims are tightly focused within a specific technical domain. Because the 1 pending office action is the only active matter, the examiner's individual interpretation of the prior art will be the decisive factor. Practitioners should prepare for a prosecution environment where the 1 distinct examiner's previous decisions in the Biotechnology & Pharmaceuticals area will heavily influence the outcome of the 1 pending action.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| JOSEPH, JANET | 1 | 40.0% | +51.3% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17268657 | TREATMENT OF HEPATITIS DELTA VIRUS INFECTION WITH INTERFERON LAMBDA | JOSEPH, JANET | 26d overdue |
| Art Unit | Apps |
|---|---|
| 1611 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17268657 | TREATMENT OF HEPATITIS DELTA VIRUS INFECTION WITH INTERFERON LAMBDA | JOSEPH, JANET | 1611 | §103Other | Final Rejection | 26d overdue | Pending | Feb 17, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialEit Pharma Inc. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Janet Joseph has the most, with 1 of Eit Pharma Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
